Skip to main content
Erschienen in: Supportive Care in Cancer 8/2019

03.01.2019 | Original Article

Symptoms during chemotherapy in colorectal cancer patients

verfasst von: Kari Röhrl, Marianne Grønlie Guren, Milada Cvancarova Småstuen, Tone Rustøen

Erschienen in: Supportive Care in Cancer | Ausgabe 8/2019

Einloggen, um Zugang zu erhalten

Abstract

Purpose

Colorectal cancer (CRC) patients experience several physical and psychological co-occurring symptoms, but little is known about symptom variation during chemotherapy cycles. Therefore, the aims were (1) to assess the occurrence and severity of frequently occurring symptoms (worrying, lack of energy, numbness/tingling, nausea, and pain) at multiple time points during chemotherapy, (2) to investigate differences in symptom trajectories between chemotherapy groups, and (3) to determine whether selected patient and clinical characteristics are associated with symptom severity throughout the treatment trajectory.

Methods

In total, 120 CRC patients receiving chemotherapy with curative or palliative intent completed the Memorial Symptom Assessment Scale (MSAS), Self-Administered Comorbidity Questionnaire (SCQ-19), and Karnofsky Performance Status (KPS) scale eight times, during two cycles of chemotherapy and 3 and 6 months after enrolment. Data were analyzed using linear mixed models for repeated measures to assess the effects of selected variables on outcomes over time.

Results

The patients experienced greatest symptom severity in the days following the administration of chemotherapy; these were lack of energy, numbness/tingling (oxaliplatin group), and nausea. Palliative patients reported significantly higher pain scores compared with curative patients over time, whereas the severity of worrying decreased over time in both treatment groups. Age, sex, educational level, performance status, treatment intent and type of chemotherapy were significantly associated with symptom severity throughout the chemotherapy trajectory.

Conclusion

Clinicians can use these findings to identify and inform patients about risk for more severe symptom burden, in order to offer supportive care at the right time during the chemotherapy treatment.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
1.
Zurück zum Zitat Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, Jemal A (2015) Global cancer statistics, 2012. CA Cancer J Clin 65(2):87–108CrossRefPubMed Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, Jemal A (2015) Global cancer statistics, 2012. CA Cancer J Clin 65(2):87–108CrossRefPubMed
2.
Zurück zum Zitat Pettersson G, Bertero C, Unosson M, Borjeson S (2014) Symptom prevalence, frequency, severity, and distress during chemotherapy for patients with colorectal cancer. Support Care Cancer 22(5):1171–1179CrossRefPubMed Pettersson G, Bertero C, Unosson M, Borjeson S (2014) Symptom prevalence, frequency, severity, and distress during chemotherapy for patients with colorectal cancer. Support Care Cancer 22(5):1171–1179CrossRefPubMed
3.
Zurück zum Zitat Rohrl K, Guren MG, Miaskowski C, Cooper BA, Diep LM, Rustoen T (2016) No differences in symptom burden between colorectal Cancer patients receiving curative versus palliative chemotherapy. J Pain Symptom Manag 52(4):539–547CrossRef Rohrl K, Guren MG, Miaskowski C, Cooper BA, Diep LM, Rustoen T (2016) No differences in symptom burden between colorectal Cancer patients receiving curative versus palliative chemotherapy. J Pain Symptom Manag 52(4):539–547CrossRef
4.
Zurück zum Zitat Tantoy IY, Cooper BA, Dhruva A et al (2018) Changes in the occurrence, severity, and distress of symptoms in patients with gastrointestinal cancers receiving chemotherapy. J Pain Symptom Manag 55(3):808–834 Tantoy IY, Cooper BA, Dhruva A et al (2018) Changes in the occurrence, severity, and distress of symptoms in patients with gastrointestinal cancers receiving chemotherapy. J Pain Symptom Manag 55(3):808–834
5.
Zurück zum Zitat Lee SE, Vincent C, Finnegan L (2017) An analysis and evaluation of the theory of unpleasant symptoms. ANS Adv Nurs Sci 40(1):E16–E39PubMed Lee SE, Vincent C, Finnegan L (2017) An analysis and evaluation of the theory of unpleasant symptoms. ANS Adv Nurs Sci 40(1):E16–E39PubMed
6.
Zurück zum Zitat Kristensen A, Solheim TS, Amundsen T et al (2017) Measurement of health-related quality of life during chemotherapy—the importance of timing. Acta Oncol 56(5):737–745 Kristensen A, Solheim TS, Amundsen T et al (2017) Measurement of health-related quality of life during chemotherapy—the importance of timing. Acta Oncol 56(5):737–745
7.
Zurück zum Zitat Giesinger JM, Wintner LM, Zabernigg A, Gamper EM, Oberguggenberger AS, Sztankay MJ, Kemmler G, Holzner B (2014) Assessing quality of life on the day of chemotherapy administration underestimates patients’ true symptom burden. BMC Cancer 14:758CrossRefPubMedPubMedCentral Giesinger JM, Wintner LM, Zabernigg A, Gamper EM, Oberguggenberger AS, Sztankay MJ, Kemmler G, Holzner B (2014) Assessing quality of life on the day of chemotherapy administration underestimates patients’ true symptom burden. BMC Cancer 14:758CrossRefPubMedPubMedCentral
8.
Zurück zum Zitat Foltran L, Aprile G, Pisa FE, Ermacora P, Pella N, Iaiza E, Poletto E, Lutrino SE, Mazzer M, Giovannoni M, Cardellino GG, Puglisi F, Fasola G (2014) Risk of unplanned visits for colorectal cancer outpatients receiving chemotherapy: a case-crossover study. Support Care Cancer 22(9):2527–2533CrossRefPubMed Foltran L, Aprile G, Pisa FE, Ermacora P, Pella N, Iaiza E, Poletto E, Lutrino SE, Mazzer M, Giovannoni M, Cardellino GG, Puglisi F, Fasola G (2014) Risk of unplanned visits for colorectal cancer outpatients receiving chemotherapy: a case-crossover study. Support Care Cancer 22(9):2527–2533CrossRefPubMed
9.
Zurück zum Zitat Andre T, de Gramont A, Vernerey D et al (2015) Adjuvant fluorouracil, leucovorin, and oxaliplatin in stage II to III colon cancer: updated 10-year survival and outcomes according to BRAF mutation and mismatch repair status of the MOSAIC study. J Clin Oncol 33(35):4176–4187CrossRefPubMed Andre T, de Gramont A, Vernerey D et al (2015) Adjuvant fluorouracil, leucovorin, and oxaliplatin in stage II to III colon cancer: updated 10-year survival and outcomes according to BRAF mutation and mismatch repair status of the MOSAIC study. J Clin Oncol 33(35):4176–4187CrossRefPubMed
10.
Zurück zum Zitat Schmoll HJ, Van Cutsem E, Stein A et al (2012) ESMO consensus guidelines for management of patients with colon and rectal cancer. A personalized approach to clinical decision making. Ann Oncol 23(10):2479–2516CrossRefPubMed Schmoll HJ, Van Cutsem E, Stein A et al (2012) ESMO consensus guidelines for management of patients with colon and rectal cancer. A personalized approach to clinical decision making. Ann Oncol 23(10):2479–2516CrossRefPubMed
11.
Zurück zum Zitat Van Cutsem E, Cervantes A, Adam R et al (2016) ESMO consensus guidelines for the management of patients with metastatic colorectal cancer. Ann Oncol 27(8):1386–1422CrossRefPubMed Van Cutsem E, Cervantes A, Adam R et al (2016) ESMO consensus guidelines for the management of patients with metastatic colorectal cancer. Ann Oncol 27(8):1386–1422CrossRefPubMed
12.
Zurück zum Zitat Basch E, Deal AM, Kris MG, Scher HI, Hudis CA, Sabbatini P, Rogak L, Bennett AV, Dueck AC, Atkinson TM, Chou JF, Dulko D, Sit L, Barz A, Novotny P, Fruscione M, Sloan JA, Schrag D (2016) Symptom monitoring with patient-reported outcomes during routine cancer treatment: a randomized controlled trial. J Clin Oncol 34(6):557–565CrossRefPubMed Basch E, Deal AM, Kris MG, Scher HI, Hudis CA, Sabbatini P, Rogak L, Bennett AV, Dueck AC, Atkinson TM, Chou JF, Dulko D, Sit L, Barz A, Novotny P, Fruscione M, Sloan JA, Schrag D (2016) Symptom monitoring with patient-reported outcomes during routine cancer treatment: a randomized controlled trial. J Clin Oncol 34(6):557–565CrossRefPubMed
14.
Zurück zum Zitat Cleeland CS, Zhao F, Chang VT, Sloan JA, O'Mara AM, Gilman PB, Weiss M, Mendoza TR, Lee JW, Fisch MJ (2013) The symptom burden of cancer: evidence for a core set of cancer-related and treatment-related symptoms from the Eastern Cooperative Oncology Group Symptom Outcomes and Practice Patterns study. Cancer 119(24):4333–4340CrossRefPubMed Cleeland CS, Zhao F, Chang VT, Sloan JA, O'Mara AM, Gilman PB, Weiss M, Mendoza TR, Lee JW, Fisch MJ (2013) The symptom burden of cancer: evidence for a core set of cancer-related and treatment-related symptoms from the Eastern Cooperative Oncology Group Symptom Outcomes and Practice Patterns study. Cancer 119(24):4333–4340CrossRefPubMed
15.
Zurück zum Zitat Ventzel L, Jensen AB, Jensen AR, Jensen TS, Finnerup NB (2016) Chemotherapy-induced pain and neuropathy: a prospective study in patients treated with adjuvant oxaliplatin or docetaxel. Pain 157(3):560–568CrossRefPubMed Ventzel L, Jensen AB, Jensen AR, Jensen TS, Finnerup NB (2016) Chemotherapy-induced pain and neuropathy: a prospective study in patients treated with adjuvant oxaliplatin or docetaxel. Pain 157(3):560–568CrossRefPubMed
16.
Zurück zum Zitat Seretny M, Currie GL, Sena ES, Ramnarine S, Grant R, MacLeod MR, Colvin LA, Fallon M (2014) Incidence, prevalence, and predictors of chemotherapy-induced peripheral neuropathy: a systematic review and meta-analysis. Pain 155(12):2461–2470CrossRefPubMed Seretny M, Currie GL, Sena ES, Ramnarine S, Grant R, MacLeod MR, Colvin LA, Fallon M (2014) Incidence, prevalence, and predictors of chemotherapy-induced peripheral neuropathy: a systematic review and meta-analysis. Pain 155(12):2461–2470CrossRefPubMed
17.
Zurück zum Zitat Walling AM, Weeks JC, Kahn KL, Tisnado D, Keating NL, Dy SM, Arora NK, Mack JW, Pantoja PM, Malin JL (2015) Symptom prevalence in lung and colorectal cancer patients. J Pain Symptom Manag 49(2):192–202CrossRef Walling AM, Weeks JC, Kahn KL, Tisnado D, Keating NL, Dy SM, Arora NK, Mack JW, Pantoja PM, Malin JL (2015) Symptom prevalence in lung and colorectal cancer patients. J Pain Symptom Manag 49(2):192–202CrossRef
18.
Zurück zum Zitat Walker MS, Pharm EY, Kerr J, Yim YM, Stepanski EJ, Schwartzberg LS (2012) Symptom burden & quality of life among patients receiving second-line treatment of metastatic colorectal cancer. BMC Res Notes 5:314CrossRefPubMedPubMedCentral Walker MS, Pharm EY, Kerr J, Yim YM, Stepanski EJ, Schwartzberg LS (2012) Symptom burden & quality of life among patients receiving second-line treatment of metastatic colorectal cancer. BMC Res Notes 5:314CrossRefPubMedPubMedCentral
19.
Zurück zum Zitat Vardy JL, Dhillon HM, Pond GR, Rourke SB, Bekele T, Renton C, Dodd A, Zhang H, Beale P, Clarke S, Tannock IF (2015) Cognitive function in patients with colorectal cancer who do and do not receive chemotherapy: a prospective, longitudinal, controlled study. J Clin Oncol 33(34):4085–4092CrossRefPubMedPubMedCentral Vardy JL, Dhillon HM, Pond GR, Rourke SB, Bekele T, Renton C, Dodd A, Zhang H, Beale P, Clarke S, Tannock IF (2015) Cognitive function in patients with colorectal cancer who do and do not receive chemotherapy: a prospective, longitudinal, controlled study. J Clin Oncol 33(34):4085–4092CrossRefPubMedPubMedCentral
20.
Zurück zum Zitat Berger AM, Mitchell SA, Jacobsen PB, Pirl WF (2015) Screening, evaluation, and management of cancer-related fatigue: ready for implementation to practice? CA Cancer J Clin 65(3):190–211CrossRefPubMed Berger AM, Mitchell SA, Jacobsen PB, Pirl WF (2015) Screening, evaluation, and management of cancer-related fatigue: ready for implementation to practice? CA Cancer J Clin 65(3):190–211CrossRefPubMed
21.
Zurück zum Zitat Tantoy IY, Cataldo JK, Aouizerat BE, Dhruva A, Miaskowski C (2016) A review of the literature on multiple co-occurring symptoms in patients with colorectal cancer who received chemotherapy alone or chemotherapy with targeted therapies. Cancer Nurs 39(6):437–445CrossRefPubMedPubMedCentral Tantoy IY, Cataldo JK, Aouizerat BE, Dhruva A, Miaskowski C (2016) A review of the literature on multiple co-occurring symptoms in patients with colorectal cancer who received chemotherapy alone or chemotherapy with targeted therapies. Cancer Nurs 39(6):437–445CrossRefPubMedPubMedCentral
22.
Zurück zum Zitat Berger AM, Grem JL, Visovsky C, Marunda HA, Yurkovich JM (2010) Fatigue and other variables during adjuvant chemotherapy for colon and rectal cancer. Oncol Nurs Forum 37(6):E359–E369CrossRefPubMed Berger AM, Grem JL, Visovsky C, Marunda HA, Yurkovich JM (2010) Fatigue and other variables during adjuvant chemotherapy for colon and rectal cancer. Oncol Nurs Forum 37(6):E359–E369CrossRefPubMed
23.
Zurück zum Zitat Ripamonti C, Santini D, Maranzano E, Berti M, Roila F, Group EGW (2012) Management of cancer pain: ESMO clinical practice guidelines. Ann Oncol 23(Suppl 7):vii139–vii154CrossRefPubMed Ripamonti C, Santini D, Maranzano E, Berti M, Roila F, Group EGW (2012) Management of cancer pain: ESMO clinical practice guidelines. Ann Oncol 23(Suppl 7):vii139–vii154CrossRefPubMed
24.
Zurück zum Zitat Hilarius DL, Kloeg PH, van der Wall E, van den Heuvel JJ, Gundy CM, Aaronson NK (2012) Chemotherapy-induced nausea and vomiting in daily clinical practice: a community hospital-based study. Support Care Cancer 20(1):107–117CrossRefPubMed Hilarius DL, Kloeg PH, van der Wall E, van den Heuvel JJ, Gundy CM, Aaronson NK (2012) Chemotherapy-induced nausea and vomiting in daily clinical practice: a community hospital-based study. Support Care Cancer 20(1):107–117CrossRefPubMed
25.
Zurück zum Zitat Schneider A, Kotronoulas G, Papadopoulou C, McCann L, Miller M, McBride J, Polly Z, Bettles S, Whitehouse A, Kearney N, Maguire R (2016) Trajectories and predictors of state and trait anxiety in patients receiving chemotherapy for breast and colorectal cancer: results from a longitudinal study. Eur J Oncol Nurs 24:1–7CrossRefPubMed Schneider A, Kotronoulas G, Papadopoulou C, McCann L, Miller M, McBride J, Polly Z, Bettles S, Whitehouse A, Kearney N, Maguire R (2016) Trajectories and predictors of state and trait anxiety in patients receiving chemotherapy for breast and colorectal cancer: results from a longitudinal study. Eur J Oncol Nurs 24:1–7CrossRefPubMed
26.
Zurück zum Zitat Astrup GL, Hofso K, Bjordal K et al (2017) Patient factors and quality of life outcomes differ among four subgroups of oncology patients based on symptom occurrence. Acta Oncol 56(3):462–470 Astrup GL, Hofso K, Bjordal K et al (2017) Patient factors and quality of life outcomes differ among four subgroups of oncology patients based on symptom occurrence. Acta Oncol 56(3):462–470
27.
Zurück zum Zitat Portenoy RK, Thaler HT, Kornblith AB, Lepore JM, Friedlander-Klar H, Kiyasu E, Sobel K, Coyle N, Kemeny N, Norton L (1994) The memorial symptom assessment scale: an instrument for the evaluation of symptom prevalence, characteristics and distress. Eur J Cancer 30A(9):1326–1336CrossRefPubMed Portenoy RK, Thaler HT, Kornblith AB, Lepore JM, Friedlander-Klar H, Kiyasu E, Sobel K, Coyle N, Kemeny N, Norton L (1994) The memorial symptom assessment scale: an instrument for the evaluation of symptom prevalence, characteristics and distress. Eur J Cancer 30A(9):1326–1336CrossRefPubMed
28.
Zurück zum Zitat Sangha O, Stucki G, Liang MH, Fossel AH, Katz JN (2003) The self-administered comorbidity questionnaire: a new method to assess comorbidity for clinical and health services research. Arthritis Rheum 49(2):156–163CrossRefPubMed Sangha O, Stucki G, Liang MH, Fossel AH, Katz JN (2003) The self-administered comorbidity questionnaire: a new method to assess comorbidity for clinical and health services research. Arthritis Rheum 49(2):156–163CrossRefPubMed
29.
Zurück zum Zitat Schag CC, Heinrich RL, Ganz PA (1984) Karnofsky performance status revisited: reliability, validity, and guidelines. J Clin Oncol 2(3):187–193CrossRefPubMed Schag CC, Heinrich RL, Ganz PA (1984) Karnofsky performance status revisited: reliability, validity, and guidelines. J Clin Oncol 2(3):187–193CrossRefPubMed
30.
Zurück zum Zitat Brandenbarg D, Korsten J, Berger MY, Berendsen AJ (2018) The effect of physical activity on fatigue among survivors of colorectal cancer: a systematic review and meta-analysis. Support Care Cancer 26(2):393–403 Brandenbarg D, Korsten J, Berger MY, Berendsen AJ (2018) The effect of physical activity on fatigue among survivors of colorectal cancer: a systematic review and meta-analysis. Support Care Cancer 26(2):393–403
31.
Zurück zum Zitat Agasi-Idenburg SC, Thong MS, Punt CJ, Stuiver MM, Aaronson NK (2017) Comparison of symptom clusters associated with fatigue in older and younger survivors of colorectal cancer. Support Care Cancer 25(2):625–632CrossRefPubMed Agasi-Idenburg SC, Thong MS, Punt CJ, Stuiver MM, Aaronson NK (2017) Comparison of symptom clusters associated with fatigue in older and younger survivors of colorectal cancer. Support Care Cancer 25(2):625–632CrossRefPubMed
32.
Zurück zum Zitat Roila F, Molassiotis A, Herrstedt J, Aapro M, Gralla RJ, Bruera E, Clark-Snow RA, Dupuis LL, Einhorn LH, Feyer P, Hesketh PJ, Jordan K, Olver I, Rapoport BL, Roscoe J, Ruhlmann CH, Walsh D, Warr D, van der Wetering M, participants of the MASCC/ESMO Consensus Conference Copenhagen 2015 (2016) 2016 MASCC and ESMO guideline update for the prevention of chemotherapy- and radiotherapy-induced nausea and vomiting and of nausea and vomiting in advanced cancer patients. Ann Oncol 27(suppl 5):v119–v133CrossRefPubMed Roila F, Molassiotis A, Herrstedt J, Aapro M, Gralla RJ, Bruera E, Clark-Snow RA, Dupuis LL, Einhorn LH, Feyer P, Hesketh PJ, Jordan K, Olver I, Rapoport BL, Roscoe J, Ruhlmann CH, Walsh D, Warr D, van der Wetering M, participants of the MASCC/ESMO Consensus Conference Copenhagen 2015 (2016) 2016 MASCC and ESMO guideline update for the prevention of chemotherapy- and radiotherapy-induced nausea and vomiting and of nausea and vomiting in advanced cancer patients. Ann Oncol 27(suppl 5):v119–v133CrossRefPubMed
33.
Zurück zum Zitat Laugsand EA, Jakobsen G, Kaasa S, Klepstad P (2011) Inadequate symptom control in advanced cancer patients across Europe. Support Care Cancer 19(12):2005–2014CrossRefPubMed Laugsand EA, Jakobsen G, Kaasa S, Klepstad P (2011) Inadequate symptom control in advanced cancer patients across Europe. Support Care Cancer 19(12):2005–2014CrossRefPubMed
34.
Zurück zum Zitat Hofso K, Rustoen T, Cooper BA, Bjordal K, Miaskowski C (2013) Changes over time in occurrence, severity, and distress of common symptoms during and after radiation therapy for breast cancer. J Pain Symptom Manag 45(6):980–1006CrossRef Hofso K, Rustoen T, Cooper BA, Bjordal K, Miaskowski C (2013) Changes over time in occurrence, severity, and distress of common symptoms during and after radiation therapy for breast cancer. J Pain Symptom Manag 45(6):980–1006CrossRef
35.
Zurück zum Zitat Gibson S, McConigley R (2016) Unplanned oncology admissions within 14 days of non-surgical discharge: a retrospective study. Support Care Cancer 24(1):311–317CrossRefPubMed Gibson S, McConigley R (2016) Unplanned oncology admissions within 14 days of non-surgical discharge: a retrospective study. Support Care Cancer 24(1):311–317CrossRefPubMed
36.
Zurück zum Zitat Basch E, Deal AM, Dueck AC, Scher HI, Kris MG, Hudis C, Schrag D (2017) Overall survival results of a trial assessing patient-reported outcomes for symptom monitoring during routine cancer treatment. JAMA 318:197–198CrossRefPubMedPubMedCentral Basch E, Deal AM, Dueck AC, Scher HI, Kris MG, Hudis C, Schrag D (2017) Overall survival results of a trial assessing patient-reported outcomes for symptom monitoring during routine cancer treatment. JAMA 318:197–198CrossRefPubMedPubMedCentral
Metadaten
Titel
Symptoms during chemotherapy in colorectal cancer patients
verfasst von
Kari Röhrl
Marianne Grønlie Guren
Milada Cvancarova Småstuen
Tone Rustøen
Publikationsdatum
03.01.2019
Verlag
Springer Berlin Heidelberg
Erschienen in
Supportive Care in Cancer / Ausgabe 8/2019
Print ISSN: 0941-4355
Elektronische ISSN: 1433-7339
DOI
https://doi.org/10.1007/s00520-018-4598-y

Weitere Artikel der Ausgabe 8/2019

Supportive Care in Cancer 8/2019 Zur Ausgabe

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.